Hypercoagulation in COPD: the clot thickens

Rahaghi, F.N.; Pistenmaa, C.L.

doi:10.1183/23120541.00534-2021

Cited by 9 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[42][43][44] Precipitating events like an exacerbation of COPD may lead to atherosclerotic plaque rupture and thrombosis, further modulating the risk of acute CV events. 45,46 Chronic systemic inflammation can alter structure and function of arteries, contributing to endothelial dysfunction, atherosclerotic plaque formation, platelet activation and hyperactive coagulation state. Furthermore, systemic inflammation is not a constant but varies in response to infections or to other proinflammatory stimuli and acute viral or bacterial infections can trigger myocardial infarction or stroke even in populations of people without COPD.…”

Section: Interpretation and Clinical Implicationmentioning

confidence: 99%

Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis

Müllerová

Marshall

Nigris

et al. 2022

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: The majority of patients with chronic obstructive pulmonary disease (COPD) suffer from comorbid cardiovascular (CV) disease. Accumulating evidence suggests a temporal association between COPD exacerbations and acute CV events, possibly due to lung hyperinflation, increased hypoxemia and systemic inflammation. The aims of the study were to estimate the risk of (1) acute CV events [acute myocardial infarction (AMI), CV-related death] or stroke in the months following a COPD exacerbation and (2) COPD exacerbation in the months following an acute CV event. Methods: A systematic literature review of observational studies published since 2000 was conducted by searching literature databases (Medline and Embase). Studies were eligible if conducted in adults with COPD, exposed to either COPD exacerbation or acute CV events, with outcomes of acute CV events or COPD exacerbation reported. Studies were appraised for relevance, bias and quality. Meta-analyses, using random-effect models, were performed for each outcome of interest, thus providing a pooled relative risk (RR) and its 95% confidence interval. Results: Eight studies were identified, of which seven were used for the meta-analyses examining the risk of CV events 1–3 months after an exacerbation compared with none. For stroke (six studies), RR was 1.68 (95% CI = 1.19–2.38). For AMI (six studies), RR was 2.43 (95% CI = 1.40–4.20). No studies exploring risk of exacerbation following an acute CV event were identified. Conclusion: This meta-analysis identified a markedly increased risk of stroke or AMI within a relatively short period of time following a COPD exacerbation. Although the underlying mechanisms are not fully elucidated, patients with COPD should be monitored for risk of CV outcomes after exacerbations. In addition, preventing exacerbations may decrease the risk of subsequent acute CV events. Registration: The study protocol was published via PROSPERO: International Prospective Register of Systematic Reviews (#CRD42020211055).

show abstract

Section: Interpretation and Clinical Implicationmentioning

confidence: 99%

Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis

Müllerová

Marshall

Nigris

et al. 2022

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…18 Comorbidities associated with an increased risk of long COVID, and hypercoagulability include cardiovascular disease, renal failure, venous thrombosis, cancer, and COPD. 45 Given that Africa has the lowest COVID-19 vaccination rate among continents, this could be another risk factor for long COVID in Africa. A systematic review of six studies (n=17,256,654 individuals) investigating the impact of vaccines before acute SARS-CoV-2 infection found a low level of evidence suggesting that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID infection.…”

Section: Discussionmentioning

confidence: 99%

“…18 Comorbidities associated with an increased risk of long COVID, and hypercoagulability include cardiovascular disease, renal failure, venous thrombosis, cancer, and COPD. 45…”

Section: Discussionmentioning

confidence: 99%

Burden, Causation, and Particularities of long-COVID in African populations: A rapid systematic review

Nyasulu

Tamuzi

Erasmus

2023

Preprint

View full text Add to dashboard Cite

Background: The global estimated prevalence of long COVID-19 is 43%, and the most common symptoms found globally are fatigue, confusion, or lack of confusion, and dyspnea, with prevalence rates of 23%, 14%, and 13%, respectively. However, long COVID still lacks an overall review in African populations. The aim of this review was to determine the prevalence of long COVID, its most common symptoms, comorbidities, and pathophysiological mechanisms. Methods: A systematic review of long COVID in African populations was conducted. The random effects model was used to calculate the pooled prevalence rates (95% CI). If the results could not be pooled, a narrative synthesis was performed. Results: We included 14 studies from 7 African countries, totaling 6,030 previously SARS-CoV-2 infected participants and 2,954 long COVID patients. Long COVID had a pooled prevalence of 41% [26%-56%]. Fatigue, dyspnea, and confusion or lack of concentration were the most common symptoms, with prevalence rates (95% CI) of 41% [26%-56%], 25% [12%-38%], and 40% [12%-68%], respectively. Long COVID was associated with advanced age, being female, more than three long COVID symptoms in the acute phase, initial fatigue and dyspnea, post-recovery stress, sadness, and sleep disturbances, and loss of appetite at symptoms onset, mild, moderate, and severe, pre-existing obesity, hypertension, diabetes mellitus, and the presence of any chronic illness (P ≤0.05). According to our review, high micro clot and platelet poor plasma (PPP) viscosity explain the pathophysiology of long COVID. Conclusion: Long COVID prevalence in Africa was comparable to the global prevalence. However, the prevalence of the most common symptoms was higher in Africa. Comorbidities associated with long COVID may lead to additional complications in African populations due to hypercoagulation and thrombosis.

show abstract

“…A trend towards increased D-dimer levels in COVID-19 patients was observed in our study, without reaching a statistically significant difference. This might also be due to the control group consisting of subjects with infectious diseases associated with activated and consumptive coagulation systems [51,52]. This underlines the importance of using a control group with patients with acute respiratory infections other than SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 99%

Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19

Puccini

Reinshagen

Friebel

et al. 2023

IJMS

View full text Add to dashboard Cite

Galectin-3 is a beta-galactoside-binding lectin involved in inflammation and lung fibrosis and postulated to enhance thrombosis. In COVID-19, it is considered to be a prognostic marker of severity. The aim of this study was to evaluate whether galectin-3 is associated with thrombogenicity in COVID-19. Patients with moderate-to-severe COVID-19 (COVpos; n = 55) and patients with acute respiratory diseases, but without COVID-19 (COVneg; n = 35), were included in the study. We measured the amount of galectin-3, as well as other platelet and coagulation markers, and correlated galectin-3 levels with these markers of thrombogenicity and with the SOFA Score values. We found that galectin-3 levels, as well as von Willebrand Factor (vWF), antithrombin and tissue plasminogen activator levels, were higher in the COVpos than they were in the COVneg cohort. Galectin-3 correlated positively with vWF, antithrombin and D-dimer in the COVpos cohort, but not in the COVneg cohort. Moreover, galactin-3 correlated also with clinical disease severity, as measured by the SOFA Score. In patients with acute respiratory diseases, galectin-3 can be considered as a marker not only for disease severity, but also for increased hypercoagulability. Whether galectin-3 might be a useful therapeutic target in COVID-19 needs to be assessed in future studies.

show abstract

Hypercoagulation in COPD: the clot thickens

Cited by 9 publications

References 28 publications

Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis

Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis

Burden, Causation, and Particularities of long-COVID in African populations: A rapid systematic review

Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19

Contact Info

Product

Resources

About